Eltrombopag treats low blood platelet counts to reduce risk for bleeding. Take it on an empty stomach and at least 4 hours before or 4 hours after eating dairy products and calcium fortified juices.
Eltrombopag is a prescription medication used to prevent bleeding episodes in patients with chronic immune (idiopathic) thrombocytopenia (ITP) or chronic hepatitis C virus (HCV). Eltrombopag belongs to a group of drugs called thrombopoietin receptor agonist, which work by causing the cells of the bone marrow to produce more platelets (cells that are needed for blood to clot).
This medication comes in tablet form and is taken once a day, on an empty stomach.
Common side effects of eltrombopag include nausea, diarrhea, runny or stuffy nose, and muscle aches.
How was your experience with Eltrombopag?
Eltrombopag Cautionary Labels
Uses of Eltrombopag
Eltrombopag is a prescription medicine used to treat low blood platelet counts to lower the risk for bleeding in adults with:
- chronic immune (idiopathic) thrombocytopenia (ITP), when other medicines to treat your ITP or surgery to remove the spleen have not worked well enough.
- chronic hepatitis C virus (HCV) infection before and during treatment with interferon.
This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.
Eltrombopag Brand Names
Eltrombopag may be found in some form under the following brand names:
Eltrombopag Drug Class
Eltrombopag is part of the drug class:
Side Effects of Eltrombopag
Eltrombopag may cause serious side effects. See “Drug Precautions”.
The most common side effects of eltrombopag are:
- upper respiratory tract infection; symptoms may include runny nose, stuffy nose, and sneezing
- muscle aches
- urinary tract infections; symptoms may include frequent or urgent need to urinate, low fever in some people, pain or burning with urination
- pain or swelling (inflammation) in your throat or mouth (oropharyngeal pain and pharyngitis)
- abnormal liver function tests
- abnormal skin sensations such as tingling, itching, or burning
- back pain
- ‘flu’ symptoms (influenza); symptoms may include fever, headache, tiredness, cough, sore throat, and body aches
These are not all the possible side effects of eltrombopag. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects.
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal products. Eltrombopag may affect the way certain medicines work. Certain other medicines may affect the way eltrombopag works.
Especially tell your healthcare provider if you take:
- certain medicines used to treat high cholesterol, called “statins”.
- a blood thinner medicine.
Certain medicines may keep eltrombopag from working correctly. Take eltrombopag either 4 hours before or 4 hours after taking these products:
- antacids used to treat stomach ulcers or heartburn.
- multivitamins or products that contain iron, calcium, aluminum, magnesium, selenium, and zinc which may be found in mineral supplements.
Ask your healthcare provider if you are not sure if your medicine is one that is listed above.
Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.
Eltrombopag can cause serious side effects, including:
- Liver problems: Eltrombopag may damage your liver and cause serious illness and death. You must have blood tests to check your liver before you start taking eltrombopag and during treatment with eltrombopag. Your healthcare provider will order these blood tests. In some cases eltrombopag treatment may need to be stopped. Tell your healthcare provider right away if you have any of these signs and symptoms of liver problems:
- yellowing of the skin or the whites of the eyes (jaundice)
- unusual darkening of the urine
- unusual tiredness
- right upper stomach area pain
- Bone marrow changes (increased reticulin and possible bone marrow fibrosis): Long-term use of eltrombopag may cause changes in your bone marrow. These changes may lead to abnormal blood cells or your body making less blood cells. The mild form of these bone marrow changes is called “increased reticulin” which may progress to a more severe form called “fibrosis”. The mild form may cause no problems while the severe form may cause life-threatening blood problems. Signs of bone marrow changes may show up as abnormal results in your blood tests. Your healthcare provider will decide if abnormal blood test results mean that you should have bone marrow tests or if you should stop taking eltrombopag.
- High platelet counts and higher chance for blood clots: Your chance of getting a blood clot is increased if your platelet count is too high during treatment with eltrombopag. Your chance of getting a blood clot may also be increased during treatment with eltrombopag if you have normal or low platelet counts. You may have severe problems or die from some forms of blood clots, such as clots that travel to the lungs or that cause heart attacks or strokes. Your healthcare provider will check your blood platelet counts, and change your dose or stop eltrombopag if your platelet counts get too high. Tell your healthcare provider right away if you have signs and symptoms of a blood clot in the leg, such as swelling, pain, or tenderness in your leg.
People with chronic liver disease may be at risk for a type of blood clot in the stomach area. Stomach area pain may be a symptom of this type of blood clot.
- Worsening of blood cancers: Eltrombopag is not for use in people with blood cancer or a precancerous condition called myelodysplastic syndrome (MDS). If you have one of these conditions, eltrombopag may worsen your cancer or condition and may cause you to die sooner.
- New or worsened cataracts (a clouding of the lens in the eye): New or worsened cataracts have happened in people taking eltrombopag. Your healthcare provider will check your eyes before and during your treatment with eltrombopag. Tell your healthcare provider about any changes in your eyesight while taking eltrombopag.
When you are being treated with eltrombopag, your healthcare provider will closely monitor your dose of eltrombopag and blood tests, including platelet counts and liver tests.
Avoid situations and medicines that may increase your risk of bleeding.
Eltrombopag Food Interactions
Medicines can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of eltrombopag there are no specific foods that you must exclude from your diet when receiving eltrombopag.
Before you take eltrombopag, tell your healthcare provider if you:
- have liver or kidney problems
- have or had a blood clot
- have a history of cataracts
- have had surgery to remove your spleen (splenectomy)
- have a bone marrow problem, including a blood cancer or Myelodysplastic Syndrome (MDS)
- have bleeding problems
- are Asian and you are of Chinese, Japanese, Taiwanese, or Korean ancestry, you may need a lower dose of eltrombopag.
- have any other medical conditions
- are pregnant, think you may be pregnant, or plan to get pregnant. It is not known if eltrombopag will harm an unborn baby.
- are breastfeeding or plan to breastfeed
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal products.
Eltrombopag and Pregnancy
Tell your doctor if you are pregnant or plan to become pregnant.
The FDA categorizes medications based on safety for use during pregnancy. Five categories - A, B, C, D, and X, are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy.
This medication falls into category C. There is a registry for women who become pregnant during treatment with eltrombopag. If you become pregnant, consider this registry. The purpose of the registry is to collect safety information about the health of you and your baby. Contact the registry as soon as you become aware of the pregnancy, or ask your healthcare provider to contact the registry for you. You and your healthcare provider can get information and enroll in the registry by calling 1-888-825-5249.
Eltrombopag and Lactation
Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if eltrombopag passes into your breast milk. You and your healthcare provider should decide whether you will take eltrombopag or breastfeed. You should not do both.
- Take eltrombopag exactly as your healthcare provider tells you. Do not stop using eltrombopag without talking with your healthcare provider first. Do not change your dose or schedule for taking eltrombopag unless your healthcare provider tells you to change it.
- Take eltrombopag on an empty stomach, either 1 hour before or 2 hours after eating food.
- Take eltrombopag at least 4 hours before or 4 hours after eating dairy products and calcium fortified juices.
- If you miss a dose of eltrombopag, wait and take your next scheduled dose. Do not take more than one dose of eltrombopag in one day.
- If you take too much eltrombopag, you may have a higher chance of serious side effects. Call your healthcare provider right away.
- Your healthcare provider will check your platelet count every week and change your dose of eltrombopag as needed. This will happen every week until your healthcare provider decides that your dose of eltrombopag can stay the same. After that, you will need to have blood tests every month. When you stop taking eltrombopag, you will need to have blood tests for at least 4 weeks to check if your platelet count drops too low.
- Tell your healthcare provider about any bruising or bleeding that happens while you take and after you stop taking eltrombopag.
Take eltrombopag exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.
- 50 mg taken by mouth once daily
- If you are of East Asian ancestry: 25 mg taken by mouth once daily
- Mild, moderate, or severe liver impairment: 25 mg taken by mouth once daily
- If you are of Easy Asian ancestry who also has mild, moderate, or severe liver impairment: 12.5 mg once daily
- Your doctor with adjust your dose to achieve & maintain a certain platelet level in the blood
- Maximum daily dose: 75 mg
- Discontinue if:
- no improvement is seen after 4 weeks at the maximum dose, or...
- if liver tests are abnormal, or...
- if platelet levels are too high as determined by your doctor.
Chronic Hepatitis C-associated thrombocytopenia:
- Start eltrombopag at 25 mg once daily.
- Your doctor will adjust the dose to achieve a target platelet level that is needed before you start antiviral therapy.
- Do not exceed a daily dose of 100 mg.
If you take too much eltrombopag call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away.
If eltrombopag is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.
- Store at room temperature between 59˚F to 86˚F (15˚C to 30˚C).
- Keep eltrombopag and all medicines out of the reach of children.
Eltrombopag FDA Warning
WARNING: RISK FOR HEPATOTOXICITY
Eltrombopag may cause hepatotoxicity. Eltrombopag, in combination with interferon and ribavirin in patients with chronic hepatitis C, may increase the risk of hepatic decompensation.
Measure serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin prior to initiation of eltrombopag, every 2 weeks during the dose adjustment phase, and monthly following establishment of a stable dose. If bilirubin is elevated, perform fractionation.
Evaluate abnormal serum liver tests with repeat testing within 3 to 5 days. If the abnormalities are confirmed, monitor serum liver tests weekly until the abnormality(ies) resolve, stabilize, or return to baseline levels.
Discontinue eltrombopag if ALT levels increase to ≥3X the upper limit of normal (ULN) in patients with normal liver function or ≥3X baseline in patients with pretreatment elevations in transaminases and are:
- progressive, or
- persistent for ≥4 weeks, or
- accompanied by increased direct bilirubin, or
- accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation.